Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorAdam W. Bartletten_US
dc.contributor.authorPagakrong Lumbiganonen_US
dc.contributor.authorNia Kurniatien_US
dc.contributor.authorTavitiya Sudjaritruken_US
dc.contributor.authorThahira J. Mohameden_US
dc.contributor.authorRawiwan Hansudewechakulen_US
dc.contributor.authorPenh S. Lyen_US
dc.contributor.authorKhanh H. Truongen_US
dc.contributor.authorThanyawee Puthanakiten_US
dc.contributor.authorLam V. Nguyenen_US
dc.contributor.authorKulkanya Chokephaibulkiten_US
dc.contributor.authorViet C. Doen_US
dc.contributor.authorNagalingeswaran Kumarasamyen_US
dc.contributor.authorNik Khairulddin Nik Yusoffen_US
dc.contributor.authorMoy S. Fongen_US
dc.contributor.authorDewi K. Watuen_US
dc.contributor.authorRevathy Nallusamyen_US
dc.contributor.authorAnnette H. Sohnen_US
dc.contributor.authorMatthew G. Lawen_US
dc.contributor.authorP. S. Lyen_US
dc.contributor.authorV. Kholen_US
dc.contributor.authorJ. Tuckeren_US
dc.contributor.authorN. Kumarasamyen_US
dc.contributor.authorE. Chandrasekaranen_US
dc.contributor.authorD. K. Watien_US
dc.contributor.authorD. Vedaswarien_US
dc.contributor.authorI. B. Ramajayaen_US
dc.contributor.authorD. Muktiartien_US
dc.contributor.authorS. M. Fongen_US
dc.contributor.authorM. Limen_US
dc.contributor.authorF. Dauten_US
dc.contributor.authorN. K. Nik Yusoffen_US
dc.contributor.authorP. Mohamaden_US
dc.contributor.authorM. R. Drawisen_US
dc.contributor.authorR. Nallusamyen_US
dc.contributor.authorK. C. Chanen_US
dc.contributor.authorV. Sirisanthanaen_US
dc.contributor.authorL. Aurpibulen_US
dc.contributor.authorR. Hansudewechakulen_US
dc.contributor.authorP. Ounchanumen_US
dc.contributor.authorS. Denjantaen_US
dc.contributor.authorA. Kongphonoien_US
dc.contributor.authorP. Kosalaraksaen_US
dc.contributor.authorP. Tharnprisanen_US
dc.contributor.authorT. Udomphaniten_US
dc.contributor.authorG. Jourdainen_US
dc.contributor.authorT. Puthanakiten_US
dc.contributor.authorS. Anugulruengkiten_US
dc.contributor.authorW. Jantarabenjakulen_US
dc.contributor.authorR. Nadsasarnen_US
dc.contributor.authorK. Chokephaibulkiten_US
dc.contributor.authorK. Lapphraen_US
dc.contributor.authorW. Phongsamarten_US
dc.contributor.authorS. Sricharoenchaien_US
dc.contributor.authorK. H. Truongen_US
dc.contributor.authorQ. T. Duen_US
dc.contributor.authorC. H. Nguyenen_US
dc.contributor.authorV. C. Doen_US
dc.contributor.authorT. M. Haen_US
dc.contributor.authorV. T. Anen_US
dc.contributor.authorL. V. Nguyenen_US
dc.contributor.authorD. T.K. Khuen_US
dc.contributor.authorA. N. Phamen_US
dc.contributor.authorL. T. Nguyenen_US
dc.contributor.authorO. N. Leen_US
dc.contributor.authorA. H. Sohnen_US
dc.contributor.authorJ. L. Rossen_US
dc.contributor.authorC. Sethaputraen_US
dc.contributor.authorM. G. Lawen_US
dc.contributor.authorA. Kariminiaen_US
dc.description.abstract© 2019 Society for Adolescent Health and Medicine Purpose: Antiretroviral monotherapy and treatment interruption are potential strategies for perinatally HIV-infected adolescents (PHIVA) who face challenges maintaining effective combination antiretroviral therapy (ART). We assessed the use and outcomes for adolescents receiving monotherapy or undergoing treatment interruption in a regional Asian cohort. Methods: Regional Asian data (2001–2016) were analyzed to describe PHIVA who experienced ≥2 weeks of lamivudine or emtricitabine monotherapy or treatment interruption and trends in CD4 count and HIV viral load during and after episodes. Survival analyses were used for World Health Organization (WHO) stage III/IV clinical and immunologic event-free survival during monotherapy or treatment interruption, and a Poisson regression to determine factors associated with monotherapy or treatment interruption. Results: Of 3,448 PHIVA, 84 (2.4%) experienced 94 monotherapy episodes, and 147 (4.3%) experienced 174 treatment interruptions. Monotherapy was associated with older age, HIV RNA >400 copies/mL, younger age at ART initiation, and exposure to ≥2 combination ART regimens. Treatment interruption was associated with CD4 count <350 cells/μL, HIV RNA ≥1,000 copies/mL, ART adverse event, and commencing ART age ≥10 years compared with age <3 years. WHO clinical stage III/IV 1-year event-free survival was 96% and 85% for monotherapy and treatment interruption cohorts, respectively. WHO immunologic stage III/IV 1-year event-free survival was 52% for both cohorts. Those who experienced monotherapy or treatment interruption for more than 6 months had worse immunologic and virologic outcomes. Conclusions: Until challenges of treatment adherence, engagement in care, and combination ART durability/tolerability are met, monotherapy and treatment interruption will lead to poor long-term outcomes.en_US
dc.titleUse and Outcomes of Antiretroviral Monotherapy and Treatment Interruption in Adolescents With Perinatal HIV Infection in Asiaen_US
article.title.sourcetitleJournal of Adolescent Healthen_US Medical Centre Indiaen_US Hospital of Pediatrics Hanoien_US Udayanaen_US Indonesiaen_US Universityen_US Instituteen_US of Medicine, Khon Kaen Universityen_US Lumpur Hospitalen_US of Medicine, Siriraj Hospital, Mahidol Universityen_US Mai Universityen_US's Hospital 2en_US Center for HIV/AIDSen_US's Hospital 1en_US Asia/amfAR-The Foundation for AIDS Researchen_US Hospitalen_US Prachanukroh Hospitalen_US Likasen_US Raja Perempuan Zainab IIen_US
Appears in Collections:CMUL: Journal Articles

Files in This Item:
There are no files associated with this item.

Items in CMUIR are protected by copyright, with all rights reserved, unless otherwise indicated.